959 related articles for article (PubMed ID: 25601652)
1. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.
Voron T; Colussi O; Marcheteau E; Pernot S; Nizard M; Pointet AL; Latreche S; Bergaya S; Benhamouda N; Tanchot C; Stockmann C; Combe P; Berger A; Zinzindohoue F; Yagita H; Tartour E; Taieb J; Terme M
J Exp Med; 2015 Feb; 212(2):139-48. PubMed ID: 25601652
[TBL] [Abstract][Full Text] [Related]
2. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
3. [Impact of VEGF-A in exhaustion of intratumoral T cells].
Voron T; Tartour É; Taieb J; Terme M
Med Sci (Paris); 2015 May; 31(5):473-5. PubMed ID: 26059293
[No Abstract] [Full Text] [Related]
4. Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression.
Wang Y; Sun SN; Liu Q; Yu YY; Guo J; Wang K; Xing BC; Zheng QF; Campa MJ; Patz EF; Li SY; He YW
Cancer Discov; 2016 Sep; 6(9):1022-35. PubMed ID: 27297552
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo.
Das R; Verma R; Sznol M; Boddupalli CS; Gettinger SN; Kluger H; Callahan M; Wolchok JD; Halaban R; Dhodapkar MV; Dhodapkar KM
J Immunol; 2015 Feb; 194(3):950-9. PubMed ID: 25539810
[TBL] [Abstract][Full Text] [Related]
6. The Inhibitory Signaling Receptor Protocadherin-18 Regulates Tumor-Infiltrating CD8
Frey AB
Cancer Immunol Res; 2017 Oct; 5(10):920-928. PubMed ID: 28874354
[TBL] [Abstract][Full Text] [Related]
7. PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8
Whelan S; Ophir E; Kotturi MF; Levy O; Ganguly S; Leung L; Vaknin I; Kumar S; Dassa L; Hansen K; Bernados D; Murter B; Soni A; Taube JM; Fader AN; Wang TL; Shih IM; White M; Pardoll DM; Liang SC
Cancer Immunol Res; 2019 Feb; 7(2):257-268. PubMed ID: 30659054
[TBL] [Abstract][Full Text] [Related]
8. Reversing T-cell Dysfunction and Exhaustion in Cancer.
Zarour HM
Clin Cancer Res; 2016 Apr; 22(8):1856-64. PubMed ID: 27084739
[TBL] [Abstract][Full Text] [Related]
9. Regulation of PD-1 in T cells for cancer immunotherapy.
Yu X; Gao R; Li Y; Zeng C
Eur J Pharmacol; 2020 Aug; 881():173240. PubMed ID: 32497624
[TBL] [Abstract][Full Text] [Related]
10. TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer.
Park BV; Freeman ZT; Ghasemzadeh A; Chattergoon MA; Rutebemberwa A; Steigner J; Winter ME; Huynh TV; Sebald SM; Lee SJ; Pan F; Pardoll DM; Cox AL
Cancer Discov; 2016 Dec; 6(12):1366-1381. PubMed ID: 27683557
[TBL] [Abstract][Full Text] [Related]
11. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression.
Chang CH; Qiu J; O'Sullivan D; Buck MD; Noguchi T; Curtis JD; Chen Q; Gindin M; Gubin MM; van der Windt GJ; Tonc E; Schreiber RD; Pearce EJ; Pearce EL
Cell; 2015 Sep; 162(6):1229-41. PubMed ID: 26321679
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
Li B; Lalani AS; Harding TC; Luan B; Koprivnikar K; Huan Tu G; Prell R; VanRoey MJ; Simmons AD; Jooss K
Clin Cancer Res; 2006 Nov; 12(22):6808-16. PubMed ID: 17121902
[TBL] [Abstract][Full Text] [Related]
13. Expression of immune checkpoints and T cell exhaustion markers in early and advanced stages of colorectal cancer.
Saleh R; Taha RZ; Toor SM; Sasidharan Nair V; Murshed K; Khawar M; Al-Dhaheri M; Petkar MA; Abu Nada M; Elkord E
Cancer Immunol Immunother; 2020 Oct; 69(10):1989-1999. PubMed ID: 32393998
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitors for cancer treatment.
Park J; Kwon M; Shin EC
Arch Pharm Res; 2016 Nov; 39(11):1577-1587. PubMed ID: 27770382
[TBL] [Abstract][Full Text] [Related]
15. Checkpoint Inhibitors: Conquering Cancer with a Little (T)-Help from Our Microbial Friends.
Asmar N; Ibrahim T; Rey JF
Dig Dis Sci; 2018 Sep; 63(9):2177-2179. PubMed ID: 29982987
[No Abstract] [Full Text] [Related]
16. Not All Immune Checkpoints Are Created Equal.
De Sousa Linhares A; Leitner J; Grabmeier-Pfistershammer K; Steinberger P
Front Immunol; 2018; 9():1909. PubMed ID: 30233564
[TBL] [Abstract][Full Text] [Related]
17. IL-2 regulates tumor-reactive CD8
Liu Y; Zhou N; Zhou L; Wang J; Zhou Y; Zhang T; Fang Y; Deng J; Gao Y; Liang X; Lv J; Wang Z; Xie J; Xue Y; Zhang H; Ma J; Tang K; Fang Y; Cheng F; Zhang C; Dong B; Zhao Y; Yuan P; Gao Q; Zhang H; Xiao-Feng Qin F; Huang B
Nat Immunol; 2021 Mar; 22(3):358-369. PubMed ID: 33432230
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulatory Activity of VEGF in Cancer.
Lapeyre-Prost A; Terme M; Pernot S; Pointet AL; Voron T; Tartour E; Taieb J
Int Rev Cell Mol Biol; 2017; 330():295-342. PubMed ID: 28215534
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants.
Morera Y; Bequet-Romero M; Ayala M; Lamdán H; Agger EM; Andersen P; Gavilondo JV
Angiogenesis; 2008; 11(4):381-93. PubMed ID: 19034678
[TBL] [Abstract][Full Text] [Related]
20. VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-κB-induced endothelial activation.
Huang H; Langenkamp E; Georganaki M; Loskog A; Fuchs PF; Dieterich LC; Kreuger J; Dimberg A
FASEB J; 2015 Jan; 29(1):227-38. PubMed ID: 25361735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
